GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Earnings for GH Research PLC (GHRS)
Earnings in 2023 (TTM): $-35,587,000
According to GH Research PLC's latest financial reports the company's current earnings (TTM) are $-35,587,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of GH Research PLC
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-35,587,000 | $-35,587,000 |
| 2022 | $-22,456,000 | $-7,135,000 |
| 2021 | $-9,202,000 | $-9,211,000 |
| 2020 | $-446,000 | $-446,000 |
| 2019 | $-310,000 | $-310,000 |